Clinical trial Recruiting at 7 sites Observational Ages 21 to 80

Evaluating the performance of a modular hip stem in revision hip surgeries

Official title: Medacta M-Vizion™ Macroscopic Radiographic Study, Multi-center, Post-Market Outcomes Study

Run by Medacta USA · NCT05721859 · Data updated 2026-11-12

This study is testing if a new modular hip stem can stay stable during revision hip surgeries for patients and if it will move less than 5mm over two years.

More Revision Hip Arthroplasty trials

Quick facts

Study typeObservational
Ages21 Years to 80 Years
SexAll
Enrollment70 (estimated)
SponsorMedacta USA
Industry-sponsored
Locations7 sites (Chicago, Illinois and 6 other locations)
StatusRecruiting
StartedOctober 12, 2022
Main results expectedJune 1, 2026
Study endsJune 1, 2026
Registry record updatedMay 8, 2025
Trial IDNCT05721859 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients aged 21 to 80 who require a revision total hip replacement and are receiving the M-Vizion femoral component.

Probably not a fit

Patients with neuromuscular deficiencies or systemic disorders that affect bone health may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the performance of the M-Vizion modular stem in patients undergoing revision hip arthroplasty. It focuses on measuring the subsidence of the femoral stem within the canal over a two-year period. Participants will be monitored to ensure they meet the inclusion criteria and comply with the study protocol. The study seeks to determine if the M-Vizion stem will result in less than 5mm of subsidence, indicating effective performance.

Why it matters

Potential benefit: If successful, this study could lead to improved outcomes and stability for patients undergoing revision hip arthroplasty.

How similar studies have gone: Other studies have shown promising results with similar modular hip stem approaches, indicating potential for success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Must be able to read, understand, and provide written informed consent on the Institutional Review Board (IRB) approved Informed Consent Form (ICF).
* Ability to understand and provide written authorization for use and disclosure of personal health information.
* Subjects who are able and willing to comply with the study protocol and follow-up visits.
* Patients requiring a revision total hip replacement.
* Subjects undergoing revision THA who will receive an M-Vizion femoral component according to the indications for use.
* Male and female patients ages 21 - 80 years of age at the time of surgery.

Exclusion Criteria:

* Patients with neuromuscular or neurosensory deficiency, which would limit the ability to assess the performance of the device.
* Patients with a systemic or metabolic disorder leading to progressive bone deterioration.
* Patients bone stock is compromised by disease or infection, which could possibly prevent adequate support and/or fixation to the prosthesis.
* Patients with an active or suspected latent infection in or about the hip joint.
* Patients that are incarcerated.

Where it's running

  • Northwestern Medicine
    Chicago, Illinois, United States
    Recruiting
  • New England Baptist Hospital
    Boston, Massachusetts, United States
    Recruiting
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts, United States
    Recruiting
  • Dartmouth Health
    Lebanon, New Hampshire, United States
    Recruiting
  • OrthoCarolina Research Institute, Inc.
    Charlotte, North Carolina, United States
    Recruiting
  • Geisinger Medical Center
    Danville, Pennsylvania, United States
    Recruiting
Show 1 more location
  • University of Utah Department of Orthopaedics
    Salt Lake City, Utah, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.